-
Our Technology
Universal Gene Therapy Platform
Borea Therapeutics has developed a gene therapy platform where AAV-derived viral vectors are chemically modified to strategically incorporate any ligand of choice, dramatically expanding the design space. With fully unconstrained capabilities, our platform offers unprecedented flexibility in tailoring vector properties to specific therapeutic needs.
Advanced chemical modification of any AAV capsid — wild-type or engineered — without altering its sequence.
Key Benefits:
- Works with any AAV
- Preserves original capsid performance
- Multiple characteristics conferrable
Click Chemistry Platform
Bio-orthogonal conjugation methods for precise attachment of any ligands to any AAV capsids.
Key Benefits:
- Biocompatible reactions
- Plug & Play design
- Seamless integration
Ligands
Unconstrained conjugation with a broad range of ligands – from enzymes to peptides and proteins- for fully customizable AAV design.
Key Benefits:
- Unlimited design space
- Predictable, human-relevant properties
- Higher success rates
Click Chemistry Conjugation Process
AAV Vector
Click-chemistry linker is covalently attached to the vector
Click Reaction
Bioorthogonal conjugation of ligand to reactive linker
Targeted Vector
AAV functionalised with ligand of choice
Expanding AAV capabilities through ligand-driven design
Applications of Our Platform
Enhanced Targeting
Ligands enable precise cell and tissue targeting based on receptor interactions.
Improved Biodistribution
Modify AAV surface to cross biological barriers and reach distant and hard-to-access sites.
Intracellular Delivery
Functionalize AAV with active proteins or enzymes to enable complex intracellular processes and optimize payload release.
Knowledge-Based Capsid Design Technology
Borea’s knowledge-based capsid design technology is the best suited to address AAV limitations, offering increased design options and flexibility
Flexibility
We can conjugate ligands to different AAV serotypes and attach multiple ligands to the same AAV
Versatility
We can conjugate full length proteins, scFv, short peptides, and functional enzymes
Translatability
No impact on AAV yield or potency – clear translational advantage with known ligands
Plug & Play
Modular design dramatically increases AAV therapy design options